Artiva Biotherapeutics reported the initiation of AlloNK® (AB-101) treatment in a basket trial for autoimmune diseases like rheumatoid arthritis and lupus, with initial data expected in H1 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.